Abstract:The genetic alterations associated with acute leukemia can be divided into two functional groups. The class I mutations enhance cellular proliferation and survival by constitutive activation of mainly protein tyrosine kinases signaling pathways. In contrast, the class II mutations frequently involve transcriptional regulators of normal hematopoietic differentiation, and result in a block of hematopoietic cell maturation and/or aberrant self-renewal capacity. However, expression of the class II mutations in the murine hematopoietic system often leads to myelodysplasic changes and acute leukemia after a long latency, suggesting that collaboration of additional genetic alterations might be required. To identify potential cooperating genetic events facilitating induction of acute leukemia by the class II mutations, we modeled acute myelogenous leukemia (AML) in mouse by retrovirally expressing the MLL/ENL and MOZ/TIF2 fusion genes in the bone marrow. The genetic background of leukemic mice (F1 hybrid mice resulting from crossbreeding the FVB/N and 129/s1 strains) allowed us to perform a genomewide polymorphism analysis screening for loss of heterozygosity (LOH) that is frequently found in blasts from AML patients. However, a simple sequence length polymorphism (SSLP) based allelotyping as well as a mouse 5K single nucleotide polymorphism (SNP) array analysis did not showed any LOH, indicating that large scale of LOH might be a rare event in our mouse leukemia models. Recent studies have shown that genomic insertion of retrovirus could influence the expression of adjacent genes and therefore contribute to oncogenic transformation of hematopoietic cells. The retroviral integration tagging approach has been widely used for seeking new proto-oncogenes or tumor suppressor genes, and especially for identifying collaborative events in tumor models that already harbored an initiating oncogenic event. To test the hypothesis that the integration of the provirus could act as cooperating events in our mouse leukemia models, we characterized the retroviral integration sites from 21 leukemic mice induced by retroviral expression of MLL/ENL and MOZ/TIF2 fusion genes. Sixty-six integration flanking genes were identified, and most of them have been previously linked to tumorigenesis. Further determination of their expression levels demonstrated that integration flanking genes like Tcf7, Tnfrsf1, Mn1 and Lhx2 were up-regulated, whereas Pur , Ppp2r5c, Runx3, Socs1 and Prdm2 were down-regulated. Interestingly, in a MLL/ENL leukemic mouse carrying the integration adjacent to the meningioma 1 (Mn1) gene, the clone harboring the Mn1 integration prevailed over other co-existing clones harboring different integrations. Moreover, an in vitro cellular proliferation assay showed that the overexpression of MN1 significantly enhanced proliferation and self-renewal capacity of primary bone marrow cells. These findings suggested that MN1 possesses leukemic transforming potential and might functionally collaborate with the MLL/ENL fusion in the development of the acute leukemia. In order to experimentally address this hypothesis, we performed a series of bone marrow transplant experiments. Indeed, co-expression of MN1 with MLL/ENL enhanced in vivo disease development, and resulted in a significantly reduced latency for induction of an aggressive acute leukemia than expression of MN1 or MLL/ENL alone. In addition, co-expression of MN1 increased the granulocytemacrophage progenitor (GMP) cell population expressing Gr1/Mac1, Cd34 and c-Kit with leukemia-initiating properties as shown in secondary transplantation experiments. As MN1 has been previously proposed to exert its function as a transcriptional co-activator, we also aimed to identify the potential downstream target genes by transient MN1 expression in primary bone marrow cells. Gene expression profiling experiments revealed a series of genes with known roles in normal or malignant hematopoiesis such as CD34, FLT3, HLF, and DLK1 that were upregulated in MN1 overexpressing murine leukemias, as well as pediatric acute leukemias with high MN1 levels. We also determined the MN1 levels in a large panel of pediatric acute leukemias. High MN1 expression levels were observed in 50 of 87 samples: high MN1 levels were found in a large proportion of B-cell ALL cases and in most infant leukemias that carry MLL fusions and are of B-cell origin. Additionally, siRNA-mediated MN1 knockdown resulted in cell cycle arrest and impaired clonogenic growth of human leukemia cell lines with high MN1 levels but not in cells with low (or undetectable) MN1 levels, suggesting the aberrant expression of MN1 contributes to malignant cellular proliferation, and the inhibition of MN1 could represent a new therapeutic approach. Taken together, while searching for cooperative genetic alterations in murine leukemias, we found that elevated levels of MN1 oncogene can act as a functional collaborator in MLL/ENL (and probably other class II mutations) induced leukemia through a distinct genetic program that increases the leukemia stem cell pool. In addition, we also demonstrated for the first time that high MN1 levels are found in a significant fraction of childhood acute leukemias, and important for proliferation of the leukemic cells.

Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion

Mir-196B Directly Targets Both HOXA9/MEIS1 Oncogenes and FAS Tumour Suppressor in MLL-rearranged Leukaemia.

Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia

Genetic and Clinical Characteristics of Acute B-cell Lymphoblastic Leukemia with MEF2D Fusions and Report of Two Novel MEF2D Rearrangements

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Functional Study of Novel Gene Fusions and Patterns of Epigenetic Regulator Mutations in Adult and Childhood B-Cell Acute Lymphoblastic Leukemia

Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism

Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia

Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia

MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia

Identification of Cooperating Genetic Events in Acute Leukemia

Novel MEIS1-FOXO1 Fusion Gene in a Case of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis

HDAC2-miR183-5p Epigenetic Circuit Contributes to the Growth of Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia via PTEN/AKT and c-MYC Signaling Pathway

Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL- mediated leukemia

E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction

NPM1 Mutation Mediated HOXBLINC Lncrna Activation Promotes AML Leukemogenesis

Leukemia Driven By a NUP98-Phd Domain Fusion Is Highly Sensitive To Disruption Of H3K4me3-Phd Domain Binding By a Small Molecule Inhibitor